Simulation Study of Interactions Between Two Bioactive Components from Zingiber cassumunar and 5-Lipoxygenase

Area of Science:

• Pharmacology
• Computational Chemistry
• Biochemistry

Background:

• Compound D and DMPBD are derived from Zingiber cassumunar Roxb. (Plai), a common ingredient in Thai asthma treatments.
• Despite widespread use, the precise antiasthmatic inhibition mechanisms of these compounds remain largely unelucidated.

Purpose of the Study:

• To investigate the molecular interactions and binding mechanisms of Compound D and DMPBD with the 5-lipoxygenase (5-LO) enzyme.
• To explore the potential of Compound D and DMPBD as novel therapeutic agents for asthma management.

Main Methods:

• Utilized molecular docking and molecular dynamics (MD) simulations to analyze the binding of Compound D and DMPBD to the 5-LO enzyme.
• Calculated binding energies using Molecular Mechanics Generalized Born Surface Area (MM/GBSA) to quantify interaction strength.

Main Results:

• Compound D and DMPBD were found to bind to the same active site on the 5-LO enzyme as its natural substrate, arachidonic acid.
• The binding patterns were comparable to that of Zileuton, a commercially available asthma medication.
• Calculated binding energies were -26.83 kcal/mol for Compound D and -29.15 kcal/mol for DMPBD with 5-LO.

Conclusions:

• Compound D and DMPBD function as competitive inhibitors of the 5-LO enzyme.
• Their ability to bind to the substrate-binding site suggests a viable mechanism for their antiasthmatic effects.
• These findings highlight Compound D and DMPBD as promising candidates for the development of new antiasthmatic drugs.